Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Products under Development by Stage of Development | 7 | 1 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Products under Development by Therapy Area | 8 | 1 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Products under Development by Indication | 9 | 1 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Pipeline Products Glance | 10 | 1 |
| Early Stage Products | 10 | 1 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Products under Development by Companies | 11 | 2 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Products under Development by Universities/Institutes | 13 | 2 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Therapeutics Assessment | 15 | 5 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 1 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Companies Involved in Therapeutics Development | 20 | 5 |
| Bayer AG | 20 | 1 |
| Les Laboratoires Servier SAS | 21 | 1 |
| Nerviano Medical Sciences S.r.l. | 22 | 1 |
| Netherlands Translational Research Center B.V. | 23 | 1 |
| Pfizer Inc. | 24 | 1 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Drug Profiles | 25 | 9 |
| BAY-1161909 Drug Profile | 25 | 1 |
| BAY-1217389 Drug Profile | 26 | 1 |
| CCT-271850 Drug Profile | 27 | 1 |
| CFI-402257 Drug Profile | 28 | 1 |
| NMSP-153 Drug Profile | 29 | 1 |
| NMSP-715 Drug Profile | 30 | 1 |
| NTRC-00660 Drug Profile | 31 | 1 |
| Small Molecules to Inhibit Mps1 for Breast Cancer Drug Profile | 32 | 1 |
| Small Molecules to Inhibit TTK Protein Kinase for Solid Tumor Drug Profile | 33 | 1 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Dormant Projects | 34 | 1 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Discontinued Products | 35 | 1 |
| Dual Specificity Protein Kinase TTK (TTK Protein Kinase or Cancer/Testis Antigen 96 or Monopolar Spindle 1-Like 1 or EC 2.7.12.1) Featured News &Press Releases | 36 | 2 |
| Sep 24, 2015: Servier and Nerviano Medical Sciences announce the entry of S 81694, an MPS1 inhibitor, in a first in Human clinical trial | 36 | 1 |
| Oct 29, 2012: Nerviano Medical Sciences To Present Four Posters At 24th EORTC-NCI-AACR Symposium | 36 | 2 |
| Appendix | 38 | 2 |
| Methodology | 38 | 1 |
| Coverage | 38 | 1 |
| Secondary Research | 38 | 1 |
| Primary Research | 38 | 1 |
| Expert Panel Validation | 38 | 1 |
| Contact Us | 38 | 1 |
| Disclaimer | 39 | 1 |